Full Press Release Details
Report of Voting Results
Submitted Pursuant to
Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations
In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") held on November 9, 2023, via live webcast (the "Meeting"). Each of the matters is described in greater detail in the Corporation's management information circular dated October 16, 2023 (the "Circular").
(a) The number of directors was set at five. The following are the voting results on this matter:
| FOR | % FOR | AGAINST | % AGAINST | |
| Number of Directors | 8,516,846 | 93.29% | 612,909 | 6.71% |
(b) In the Circular, management of the Corporation proposed five nominees for election as directors of the Corporation for the ensuing year or until their successors are duly elected or appointed. All five nominees were elected. The following are the voting results on this matter:
| FOR | % FOR | WITHHELD | % WITHHELD | |
| Jennifer L. Bath | 6,985,276 | 94.46% | 409,710 | 5.54% |
| Chris Buyse | 7,325,144 | 99.06% | 69,842 | 0.94% |
| Mitch Levine | 7,324,705 | 99.05% | 70,281 | 0.95% |
| Barry A. Springer | 7,324,876 | 99.05% | 70,110 | 0.95% |
| Dirk Witters | 7,335,209 | 99.19% | 59,777 | 0.81% |
(c) Grant Thornton LLP was reappointed as the Corporation's auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:
| FOR | % FOR | WITHHELD | % WITHHELD | |
| Reappointment of Auditors | 8,974,183 | 98.30% | 155,573 | 1.70% |
Dated this 16th day of November 2023.
| IMMUNOPRECISE ANTIBODIES LTD. | ||
| By: | (signed) Kristin Taylor | |
| Name: Kristin Taylor | ||
| Title: Chief Financial Officer |